The Simple Cholestatic Complaints Score is a Valid and Quick Patient-reported Outcome Measure in Primary Sclerosing Cholangitis

Overview

Journal Liver Int

Specialty Gastroenterology

Date 2020 Aug 26

PMID 32841496

Citations 4

Authors

Kim N van Munster

Marcel G W Dijkgraaf

Sara van Gennep

Ulrich Beuers

Cyriel Y Ponsioen

Affiliations

Soon will be listed here.

Abstract

Background: Measuring symptoms and disease burden in patients with primary sclerosing cholangitis (PSC) is increasingly important for daily practice and clinical trials. The Simple Cholestatic Complaints Score (SCCS) is a four-item questionnaire, that measures cholestatic symptoms (pruritus, fatigue, RUQ abdominal pain and fever) in PSC patients. The aim of this study was to evaluate reliability and validity of SCCS in a Dutch population.

Methods: The study population consisted of 212 patients from the Dutch prospective PSC registry. Data were collected via digital surveys. Reliability was evaluated by internal consistency and reproducibility. Construct-, criterion- and discriminant validity were determined. The ability to detect clinical change with SCCS was evaluated in patients who underwent endoscopic intervention. Simple Cholestatic Complaints Score collected by email and by a mobile application were compared.

Results: A total of 153 patients completed the questionnaire. Internal consistency was moderate and increased to 0.71 after removal of the fever item. Test-re-test reproducibility was high (intraclass correlation coefficient = 0.96). Criterion validity was good (all > 0.82). Construct validity was in line with a priori hypothesized correlations in 80%. SCCS was able to differentiate between clinically different groups. There was no difference between inflammatory bowel disease (IBD) and non-IBD patients. Simple Cholestatic Complaints Score was responsive to change after endoscopic intervention in successfully treated patients. Simple Cholestatic Complaints Score measurement by digital questionnaire and a mobile application was comparable.

Conclusion: The SCCS is a valid instrument to measure cholestatic symptoms in PSC patients. Because of its quick and easy to use properties it is suitable for frequent monitoring of symptoms in clinical trials and daily practice.

Citing Articles

Primary sclerosing cholangitis.

Manns M, Bergquist A, Karlsen T, Levy C, Muir A, Ponsioen C Nat Rev Dis Primers. 2025; 11(1):17.

PMID: 40082445 DOI: 10.1038/s41572-025-00600-x.

The potential of volatile organic compounds to diagnose primary sclerosing cholangitis.

van Vorstenbosch R, van Munster K, Stavropoulos G, Pachen D, van Schooten F, Ponsioen C JHEP Rep. 2024; 6(8):101103.

PMID: 39131082 PMC: 11315128. DOI: 10.1016/j.jhepr.2024.101103.

Protocol for the development of a core outcome set for clinical trials in primary sclerosing cholangitis.

Hussain N, Ma C, Hirschfield G, Walmsley M, Hanford P, Vesterhus M BMJ Open. 2024; 14(6):e080143.

PMID: 38926149 PMC: 11216047. DOI: 10.1136/bmjopen-2023-080143.

Symptom patterns in the daily life of PSC patients.

van Munster K, Dijkgraaf M, Oude Elferink R, Beuers U, Ponsioen C Liver Int. 2022; 42(7):1562-1570.

PMID: 35396817 PMC: 9325051. DOI: 10.1111/liv.15271.

The Simple Cholestatic Complaints Score is a valid and quick patient-reported outcome measure in primary sclerosing cholangitis.

van Munster K, Dijkgraaf M, van Gennep S, Beuers U, Ponsioen C Liver Int. 2020; 40(11):2758-2766.

PMID: 32841496 PMC: 7702029. DOI: 10.1111/liv.14644.

References

van der Plas S, Hansen B, de Boer J, Stijnen T, Passchier J, de Man R . The Liver Disease Symptom Index 2.0; validation of a disease-specific questionnaire. Qual Life Res. 2004; 13(8):1469-81. DOI: 10.1023/B:QURE.0000040797.17449.c0. View

Ponsioen C, Lindor K, Mehta R, Dimick-Santos L . Design and Endpoints for Clinical Trials in Primary Sclerosing Cholangitis. Hepatology. 2018; 68(3):1174-1188. DOI: 10.1002/hep.29882. View

Tavakol M, Dennick R . Making sense of Cronbach's alpha. Int J Med Educ. 2016; 2:53-55. PMC: 4205511. DOI: 10.5116/ijme.4dfb.8dfd. View

Fisk J, Ritvo P, Ross L, Haase D, Marrie T, Schlech W . Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. Clin Infect Dis. 1994; 18 Suppl 1:S79-83. DOI: 10.1093/clinids/18.supplement_1.s79. View

Ponsioen C, Lam K, van Milligen de Wit A, Huibregtse K, Tytgat G . Four years experience with short term stenting in primary sclerosing cholangitis. Am J Gastroenterol. 1999; 94(9):2403-7. DOI: 10.1111/j.1572-0241.1999.01364.x. View

Dyson J, Beuers U, Jones D, Lohse A, Hudson M . Primary sclerosing cholangitis. Lancet. 2018; 391(10139):2547-2559. DOI: 10.1016/S0140-6736(18)30300-3. View

Bolier R, de Vries E, Pares A, Helder J, Kemper E, Zwinderman K . Fibrates for the treatment of cholestatic itch (FITCH): study protocol for a randomized controlled trial. Trials. 2017; 18(1):230. PMC: 5442649. DOI: 10.1186/s13063-017-1966-8. View

Ponsioen C, Arnelo U, Bergquist A, Rauws E, Paulsen V, Cantu P . No Superiority of Stents vs Balloon Dilatation for Dominant Strictures in Patients With Primary Sclerosing Cholangitis. Gastroenterology. 2018; 155(3):752-759.e5. DOI: 10.1053/j.gastro.2018.05.034. View

Younossi Z, Afendy A, Stepanova M, Racila A, Nader F, Gomel R . Development and validation of a primary sclerosing cholangitis-specific patient-reported outcomes instrument: The PSC PRO. Hepatology. 2017; 68(1):155-165. DOI: 10.1002/hep.29664. View

10.

Patel S, Vasavda C, Ho B, Meixiong J, Dong X, Kwatra S . Cholestatic pruritus: Emerging mechanisms and therapeutics. J Am Acad Dermatol. 2019; 81(6):1371-1378. PMC: 7825249. DOI: 10.1016/j.jaad.2019.04.035. View

11.

van Gennep S, Evers S, Rietdijk S, Gielen M, de Boer N, Gecse K . High Disease Burden Drives Indirect Costs in Employed Inflammatory Bowel Disease Patients: The WORK-IBD Study. Inflamm Bowel Dis. 2020; 27(3):352-363. PMC: 7885332. DOI: 10.1093/ibd/izaa082. View

12.

Elman S, Hynan L, Gabriel V, Mayo M . The 5-D itch scale: a new measure of pruritus. Br J Dermatol. 2009; 162(3):587-93. PMC: 2875190. DOI: 10.1111/j.1365-2133.2009.09586.x. View

13.

Cheung A, Patel H, Meza-Cardona J, Cino M, Sockalingam S, Hirschfield G . Factors that Influence Health-Related Quality of Life in Patients with Primary Sclerosing Cholangitis. Dig Dis Sci. 2016; 61(6):1692-9. DOI: 10.1007/s10620-015-4013-1. View

14.

Boonstra K, Weersma R, van Erpecum K, Rauws E, Spanier B, Poen A . Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology. 2013; 58(6):2045-55. DOI: 10.1002/hep.26565. View

15.

Terwee C, Bot S, de Boer M, van der Windt D, Knol D, Dekker J . Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol. 2006; 60(1):34-42. DOI: 10.1016/j.jclinepi.2006.03.012. View

16.

van Munster K, Dijkgraaf M, van Gennep S, Beuers U, Ponsioen C . The Simple Cholestatic Complaints Score is a valid and quick patient-reported outcome measure in primary sclerosing cholangitis. Liver Int. 2020; 40(11):2758-2766. PMC: 7702029. DOI: 10.1111/liv.14644. View

17.

Cronbach L, Meehl P . Construct validity in psychological tests. Psychol Bull. 1955; 52(4):281-302. DOI: 10.1037/h0040957. View

18.

Isa F, Turner G, Kaur G, Kyte D, Slade A, Pankhurst T . Patient-reported outcome measures used in patients with primary sclerosing cholangitis: a systematic review. Health Qual Life Outcomes. 2018; 16(1):133. PMC: 6034220. DOI: 10.1186/s12955-018-0951-6. View

19.

Calvert M, Blazeby J, Altman D, Revicki D, Moher D, Brundage M . Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013; 309(8):814-22. DOI: 10.1001/jama.2013.879. View

20.

. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes. 2006; 4:79. PMC: 1629006. DOI: 10.1186/1477-7525-4-79. View